The Ascension Health-backed ophthalmic treatment developer will use the proceeds to advance its lead product through Phase 2 and 3 clinical trials.
US-based biotechnology company Ocular Therapeutix has filed for an initial public offering that could raise up to $86.25m.
Founded in 2006, Ocular develops hydrogels for ophthalmic treatments. It has raised approximately $68.4m in funding from Ascension Health Ventures, the corporate venturing unit owned by healthcare company Ascension Health, Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta, and Baxter Ventures, according to press releases and SEC filings.
Ascension is currently Ocular’s fourth largest shareholder, with a 12.5% stake. Versant holds 19%,…
